Effect of Smart Watch and App on PAP Adherence in OSA (Watch-OSA)

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Sep 3, 2022

Keywords

ClinConnect Summary

The Watch-OSA clinical trial is studying whether using a smart watch and a connected app can help people stick to their positive airway pressure (PAP) treatment for obstructive sleep apnea (OSA). PAP treatment is very effective, but many patients struggle to use it consistently. The smart watch and app can track important health information like sleep patterns, snoring, and oxygen levels, which may encourage patients to use their PAP devices more regularly.

To participate in this trial, you need to be an adult diagnosed with OSA and not currently using PAP therapy or not using it often. The trial is open to all genders and has specific criteria, such as not having certain medical conditions or using a smart watch in the past 90 days. If you join, you can expect to wear the smart watch and use the app, and researchers will monitor how these tools affect your adherence to PAP treatment. This study aims to find new ways to help patients stick to their treatment, ultimately improving their health and quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • diagnosed with OSA (apnea-hyponea index \[AHI\])≥ 5 /h) by type 1 polysomnography
• • no prior use of PAP (CPAP or auto-adjusting PAP \[APAP\]), or no prior use of PAP within the previous 90 days in patients who had received PAP therapy, or current PAP users with average daily usage (all days) \< 4 hours within the previous 90 days
• Exclusion Criteria:
• • patients who refuse PAP therapy
• • patients who have used a smart watch (e.g., Galaxy Watch, Apple Watch, etc.) within the previous 90 days
• • patients with central sleep apnea or neuromuscular disease
• • patients receiving supplemental oxygen therapy due to underlying diseases including heart failure, stroke, chronic obstructive pulmonary disease, interstitial pulmonary disease, hypoventilation syndrome, or whose baseline oxygen saturation is less than 90%
• • patients with implanted cardiac pacemakers, defibrillators, or other electronic devices
• • patients who are inexperienced in using smartphones, apps, or smart watches
• • patients with an inability or unwillingness to provide informed consent